Keratoacanthoma - Keratoakantom
☆ AI Dermatology — Free Service
I 2022 Stiftung Warentest-resultatene fra Tyskland var forbrukertilfredsheten med ModelDerm bare litt lavere enn med betalte telemedisinkonsultasjoner.
I 2022 Stiftung Warentest-resultatene fra Tyskland var forbrukertilfredsheten med ModelDerm bare litt lavere enn med betalte telemedisinkonsultasjoner.
Typisk keratoakantom (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) er en hyppig hudsvulst som er kjent for sin raske vekst og sitt potensial til å gå tilbake av seg selv. Den forekommer vanligvis hos eldre, lyshudede menn med en historie med solskader. Mens kirurgisk fjerning ved eksisjon eller Mohs mikrografisk kirurgi er den vanlige behandlingen, finnes det flere andre terapialternativer tilgjengelig.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) er en lavgradig svulst som oppstår i visse hudkjertler og ligner på squamous cell carcinoma (SCC) når den undersøkes under mikroskop. Det pågår en debatt om hvorvidt KA skal klassifiseres som en form for invasiv SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) er den nest vanligste krefttypen hos mennesker, spesielt blant eldre individer. Kirurgi brukes vanligvis til å behandle cSCC, men for noen pasienter som ikke kan opereres eller velger å la være, kan andre alternativer som intralesjonelle behandlinger vurderes. Tradisjonelle intralesjonelle behandlinger (methotrexate eller 5-fluorouracil) har blitt brukt, men det pågår forskning på nye tilnærminger som intralesjonell immunterapi og onkolytisk viroterapi. Her vil vi se på forskjellige intralesjonelle behandlinger for cSCC, alt fra klassiske metoder til banebrytende strategier.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Under mikroskopet ligner Keratoakantom (Keratoacanthoma) svært mye på plateepitelkarsinom. Mens noen patologer klassifiserer Keratoakantom (Keratoacanthoma) som en distinkt enhet og ikke som en malignitet, utvikler omtrent 6 % av kliniske og histologiske tilfeller av Keratoakantom (Keratoacanthoma) seg til invasiv og aggressiv plateepitelkreft.
○ Diagnose og behandling
#Dermoscopy
#Skin biopsy